LTR Pharma has been featured in Stockhead following the announcement that patient recruitment for its pivotal clinical study of SPONTAN® has opened.
An excerpt:
“The global ED market is forecast to increase to US$5.94 billion by 2028, growing at a CAGR of 7.1%.
With such strong demand for effective ED treatments, LTP hit the Aussie bourse on December 11, 2023, after a heavily oversubscribed IPO, including strong institutional support with eight fund managers on the register.
It rose 65% in its first month as a public company to be the top ASX IPO performer of 2023.”